These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8409695)

  • 1. Anthracycline toxicity, iron and oxygen radicals, and chelation therapy.
    Gutteridge JM
    J Lab Clin Med; 1993 Sep; 122(3):228-9. PubMed ID: 8409695
    [No Abstract]   [Full Text] [Related]  

  • 2. New iron chelators in anthracycline-induced cardiotoxicity.
    Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
    Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of anthracycline cardiotoxicity by iron chelation.
    Hershko C; Pinson A; Link G
    Acta Haematol; 1996; 95(1):87-92. PubMed ID: 8604592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of iron and oxygen-derived free radicals in ischemia-reperfusion injury.
    Kirschner RE; Fantini GA
    J Am Coll Surg; 1994 Jul; 179(1):103-17. PubMed ID: 8019714
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of iron and iron chelators in anthracycline cardiotoxicity.
    Hershko C; Link G; Tzahor M; Pinson A
    Leuk Lymphoma; 1993 Oct; 11(3-4):207-14. PubMed ID: 8260895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidant-induced iron signaling in Doxorubicin-mediated apoptosis.
    Kotamraju S; Kalivendi SV; Konorev E; Chitambar CR; Joseph J; Kalyanaraman B
    Methods Enzymol; 2004; 378():362-82. PubMed ID: 15038980
    [No Abstract]   [Full Text] [Related]  

  • 7. Iron chelation for the treatment of uveitis.
    Chen J; Zhou J; Kelly M; Holbein BE; Lehmann C
    Med Hypotheses; 2017 Jun; 103():1-4. PubMed ID: 28571790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary toxicity of deferoxamine in iron-poisoned mice.
    Adamson IY; Sienko A; Tenenbein M
    Toxicol Appl Pharmacol; 1993 May; 120(1):13-9. PubMed ID: 8511775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron chelation: deciphering novel molecular targets for cancer therapy. The tip of the iceberg of a web of iron-regulated molecules.
    Saletta F; Kovacevic Z; Richardson DR
    Future Med Chem; 2011 Dec; 3(16):1983-6. PubMed ID: 22098348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture.
    Hershko C; Link G; Tzahor M; Kaltwasser JP; Athias P; Grynberg A; Pinson A
    J Lab Clin Med; 1993 Sep; 122(3):245-51. PubMed ID: 8409700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
    van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
    Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron: a new target for pharmacological intervention in neurodegenerative diseases.
    Whitnall M; Richardson DR
    Semin Pediatr Neurol; 2006 Sep; 13(3):186-97. PubMed ID: 17101458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of adriamycin toxicity by iron chelates is not a free radical mechanism.
    Gelvan D
    Biol Trace Elem Res; 1997 Mar; 56(3):295-309. PubMed ID: 9197926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the mechanism of metabolism-dependent valproic acid-induced in vitro cytotoxicity.
    Tabatabaei AR; Thies RL; Abbott FS
    Chem Res Toxicol; 1999 Apr; 12(4):323-30. PubMed ID: 10207120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
    Gattermann N
    Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron metabolism and iron chelation in sickle cell disease.
    Walter PB; Harmatz P; Vichinsky E
    Acta Haematol; 2009; 122(2-3):174-83. PubMed ID: 19907155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis and prevention of doxorubicin cardiomyopathy.
    Ferrans VJ; Clark JR; Zhang J; Yu ZX; Herman EH
    Tsitologiia; 1997; 39(10):928-37. PubMed ID: 9505340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).
    Di Tucci AA; Murru R; Alberti D; Rabault B; Deplano S; Angelucci E
    Eur J Haematol; 2007 Jun; 78(6):540-2. PubMed ID: 17391307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemistry of dexrazoxane and analogues.
    Hasinoff BB
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):3-9. PubMed ID: 9768817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
    Chaston TB; Richardson DR
    Am J Hematol; 2003 Jul; 73(3):200-10. PubMed ID: 12827659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.